THZ1, a covalent CDK7/12/13 inhibitor, exerts antitumor activity through transcriptional regulation by inhibiting CDK7 in acute T cell leukemia, MYCN-amplified neuroblastoma, small cell lung cancer, and triple-negative breast cancer (169–172). The gene discussed is CDK7; the disease is triple-negative breast carcinoma.